GGrantIndex
← Leaderboards

H. Joachim Deeg

Fred Hutchinson Cancer Research Center

$6,774,714
Attributed
$6,774,714
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $860.9K · FY200513
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$6,774,714 · 7

By mechanism

R01$4,991,304 · 3
P01$1,229,174 · 2
R21$544,720 · 1
N01$9,516 · 1

Top collaborators

No co-investigators on record.

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsHematopoieticPreventPatternHuman SubjectChronicHuman Therapy EvaluationTransplantationT-LymphocyteLeadAcuteMarrowCyclophosphamideIn VivoToxic EffectDyserythropoietic AnemiaAllogenicConditioningReportingMortality Vital StatisticsBusulfanDysmyelopoietic SyndromesIn VitroTransplant Recipients

Grant awards (24)

Hematopoietic Cell Transplantation and Iron Overload$417,143
R01 · FY2013 · HL · contact PI
Hematopoietic Cell Transplantation and Iron Overload$438,137
R01 · FY2012 · HL · contact PI
Hematopoietic Cell Transplantation and Iron Overload$442,525
R01 · FY2011 · HL · contact PI
Hematopoietic Cell Transplantation and Iron Overload$461,487
R01 · FY2010 · HL · contact PI
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes$164,827
P01 · FY2010 · HL · contact PI
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes$162,131
P01 · FY2009 · HL · contact PI
Cell Death and Clonal Survival in Myelodysplastic Syndr*$410,088
R01 · FY2008 · HL · contact PI
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes$156,441
P01 · FY2008 · HL · contact PI
Cell Death and Clonal Survival in Myelodysplastic Syndr*$410,088
R01 · FY2007 · HL · contact PI
WT1 Expression in Patients with MDS Treated with ATG an*$268,352
R21 · FY2007 · CA · contact PI
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes$166,933
P01 · FY2007 · HL · contact PI
Cell Death and Clonal Survival in Myelodysplastic Syndr*$422,336
R01 · FY2006 · HL · contact PI
WT1 Expression in Patients with MDS Treated with ATG an*$276,368
R21 · FY2006 · CA · contact PI
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes$162,201
P01 · FY2006 · HL · contact PI
Cell Death and Clonal Survival in Myelodysplastic Syndr*$432,500
R01 · FY2005 · HL
TRANSPLANTS FOR MYELODYSPLASIA AND MYELOFIBROSIS$416,641
P01 · FY2003 · HL
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME$389,250
R01 · FY2003 · CA
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME$389,250
R01 · FY2002 · CA
TRANSPLANTS FOR MYELODYSPLASIA AND MYELOFIBROSIS$0
P01 · FY2002 · HL
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME$389,250
R01 · FY2001 · CA
TRANSPLANTS FOR MYELODYSPLASIA AND MYELOFIBROSIS$0
P01 · FY2001 · HL
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME$389,250
R01 · FY2000 · CA
CANCER FOLLOWING BONE MARROW TRANSPLANTATION$4,758
N01 · FY2000 · CP
CANCER FOLLOWING BONE MARROW TRANSPLANTATION$4,758
N01 · FY2000 · CP